Table 1. Baseline Characteristics of 82 Patients Enrolled in OpACIN and OpACIN-neo.
| Characteristic | No. (%)a |
|---|---|
| Study | |
| OpACIN | 9 (11) |
| OpACIN-neo | 73 (89) |
| Institute | |
| NKI | 42 (51) |
| MIA | 38 (46) |
| KS | 2 (2) |
| Age, median (range), y | 58.5 (18-80) |
| Sex | |
| Male | 48 (59) |
| Female | 34 (41) |
| Clinical tumor stage (AJCC 8th edition) | |
| IIIB | 51 (62) |
| IIIC | 31 (38) |
| Previous lymph node surgical procedure | |
| Previous sentinel node biopsy | 25 (30) |
| Previous lymph node dissection | 6 (8) |
| Location of affected lymph node | |
| Neck | 13 (16) |
| Axilla | 42 (51) |
| Axilla plus neck | 3 (4) |
| Groin | 23 (28) |
| Epitrochlear fossa | 1 (1) |
| No. of target lesions on CT | |
| 1 | 66 (80) |
| ≥2 | 16 (20) |
| Sum of diameter target lesions, median (IQR), mm | 24 (17.25-36.25) |
| Presurgical treatment regimen | |
| 2x I3N1 | 35 (43) |
| 2x I1N3 | 25 (30) |
| 2x I3 followed by 2x N3 | 22 (27) |
Abbreviations: AJCC, American Joint Committee on Cancer; IxNx, ipilimumab x mg/kg plus nivolumab x mg/kg; KS, Karolinska University Hospital; MIA, Melanoma Institute Australia; NKI, Netherlands Cancer Institute; OpACIN, Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients; OpACIN-neo, Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab.
a
Percentages may not total 100 due to rounding.